Abstract 497P
Background
The primary site of colorectal cancer (CRC) influences survival outcomes when metastasized to the liver or lung, with left-sided CRC being associated with longer survival than right-sided CRC. Additionally, the timing of metastasis, whether synchronous or metachronous, has been suggested as a factor for survival, with synchronous metastasis generally considered more aggressive than metachronous CRC with brain metastasis (BM). We investigated the effect of both CRC’s primary location and metastatic timing on overall survival (OS) upon metastasis to the brain.
Methods
We systematically searched PubMed, Embase, and the Cochrane Library. We included studies that described patients diagnosed with BM from CRC, with reports on survival outcomes based on different primary tumor sites (left vs right) or metastatic timing (synchronous vs metachronous). Within the eligible studies, we extracted hazard ratios (HR) for OS and conducted a meta-analysis by using the random-effect model.
Results
Out of 5836 studies identified through our search, 7 studies met the inclusion criteria for the meta-analysis. Similar to lung and liver metastasis of CRC, left-sided primary CRC exhibits better OS than right-sided CRC (multivariate HR = 0.71, 95% CI: 0.54-0.94, univariate HR = 0.75, 95% CI: 0.57-0.99) when metastasized to the brain. Regarding the timing of metastasis, we found no significant difference in OS between synchronous and metachronous metastasis (HR = 0.83, 95% CI: 0.48-1.43). Table: 497P
Hazard ratio of the included studies
Study | HR | 95% CI | |
Right colon vs left colon (reference = right), multivariate analysis | |||
Bergen 2021 | 0.65 | 0.46-0.92 | |
Chen 2022 | 0.94 | 0.56-1.57 | |
Chen 2023 | 0.49 | 0.18-1.34 | |
Total | 0.71 | 0.54-0.94 | I2: 0% |
Right colon vs left colon (reference = right), univariate analysis | |||
Bergen 2021 | 0.63 | 0.44-0.89 | |
Bonadio 2021 | 1.14 | 0.80-1.62 | |
Chen 2022 | 0.74 | 0.48-1.14 | |
Chen 2023 | 0.37 | 0.17-0.81 | |
Michl 2015 | 0.79 | 0.57-1.09 | |
Total | 0.75 | 0.57-0.99 | I2: 58% |
Synchronous vs metachronous (reference = metachronous), univariate analysis | |||
Chen 2023 | 0.83 | 0.44-1.58 | |
Mege 2013 | 0.50 | 0.10-2.60 | |
Tanriverdi 2014 | 1.14 | 0.31-4.13 | |
Total | 0.83 | 0.48-1.43 | I2: 0% |
Abbreviations: HR, hazard ratio; CI, confidence interval
Conclusions
Left-sided colon cancer exhibited higher OS compared to right-sided colon cancer, consistent with findings in lung and liver metastasis. However, OS did not differ between synchronous and metachronous metastasis. Further studies comparing the genotypes and mutations of CRC with BM based on their primary location and metastatic timing are warranted.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
556P - Predicting the efficacy of neoadjuvant chemoradiotherapy in rectal cancer patients based on dynamic tumor-informed ctDNA-MRD
Presenter: Weiwei Xiao
Session: Poster session 16
557P - Three-year update of real-world evaluation of ColonAiQ for colorectal cancer screening in asymptomatic individuals
Presenter: Baohua Wang
Session: Poster session 16
558P - Survival benefit of adjuvant chemotherapy based on molecular residual disease detection in resected colorectal liver metastases: Subgroup analysis from CIRCULATE-Japan GALAXY
Presenter: Kozo Kataoka
Session: Poster session 16
561P - Liquid biopsy tracking of immunotherapy-induced T cell dynamics in MSS colorectal and endometrial tumors
Presenter: Holger Heyn
Session: Poster session 16
562P - Acquired genomic alterations on first-line chemotherapy (CT) + cetuximab in advanced colorectal cancer (mCRC): Circulating tumor (ct)DNA analysis of the randomized phase II trial TIME-PRODIGE-28
Presenter: Valerie Boige
Session: Poster session 16
564P - Short-course radiotherapy combined with chemotherapy and PD-1 inhibitor in proficient mismatch repair or microsatellite stable (pMMR/MSS) low-lying early rectal cancer: Preliminary findings from a prospective, multi-center, phase II trial (TORCH-E)
Presenter: Fan Xia
Session: Poster session 16
565P - Neoadjuvant chemotherapy, excision, and observation for early rectal cancer: The phase II NEO trial (CCTG CO.28) results after minimum 3 years follow up
Presenter: Carl Brown
Session: Poster session 16